[{"address1": "Carl Jacobsens Vej 30", "address2": "Valby", "city": "Copenhagen", "zip": "2500", "country": "Denmark", "phone": "45 70 20 27 28", "website": "https://www.genmab.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1042, GEN1059, GEN1055, and GEN1057 for solid tumors; GEN3014 for hematologic malignancies; GEN1160 for advanced solid and liquid tumors; and GEN1107 and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Novartis International AG, Medarex, Inc., ADC Therapeutics SA, Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Immatics, Novo Nordisk A/S, CureVac AG, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.", "fullTimeEmployees": 2681, "companyOfficers": [{"maxAge": 1, "name": "Dr. Jan G.J. van de Winkel Ph.D.", "age": 63, "title": "Co-Founder, President & CEO", "yearBorn": 1961, "fiscalYear": 2024, "totalPay": 3206166, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Anthony  Pagano C.P.A.", "age": 46, "title": "Executive VP & CFO", "yearBorn": 1978, "fiscalYear": 2024, "totalPay": 1178738, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Rayne  Waller", "age": 56, "title": "Executive VP & Chief Technical Operations Officer", "yearBorn": 1968, "fiscalYear": 2024, "totalPay": 798398, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Christopher  Cozic", "age": 46, "title": "Executive VP & Chief People Officer", "yearBorn": 1978, "fiscalYear": 2024, "totalPay": 864408, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Martine J. van Vugt Ph.D.", "age": 53, "title": "Executive VP & Chief Strategy Officer", "yearBorn": 1971, "fiscalYear": 2024, "totalPay": 817258, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Martin  Schultz", "age": 49, "title": "Senior Director, Head of Development Business Partnership & Strategy and Director", "yearBorn": 1975, "fiscalYear": 2024, "totalPay": 220031, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Judith V. Klimovsky M.D.", "age": 66, "title": "Executive VP & Chief Development Officer", "yearBorn": 1958, "fiscalYear": 2024, "totalPay": 1335903, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Tahamtan  Ahmadi M.D., Ph.D.", "age": 52, "title": "Executive VP, Chief Medical Officer & Head of Experimental Medicines", "yearBorn": 1972, "fiscalYear": 2024, "totalPay": 1241604, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Mijke  Zachariasse Ph.D.", "age": 51, "title": "VP, Head of Antibody Research Materials & Director", "yearBorn": 1973, "fiscalYear": 2024, "totalPay": 251464, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Takahiro  Hamatani", "age": 49, "title": "Senior Director of Finance Japan & Non-Independent Director", "yearBorn": 1975, "fiscalYear": 2024, "totalPay": 220031, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "irWebsite": "http://ir.genmab.com/index.cfm", "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 32.3, "open": 31.81, "dayLow": 31.24, "dayHigh": 31.9, "regularMarketPreviousClose": 32.3, "regularMarketOpen": 31.81, "regularMarketDayLow": 31.24, "regularMarketDayHigh": 31.9, "payoutRatio": 0.0, "beta": 0.792, "trailingPE": 13.672489, "forwardPE": 20.667212, "volume": 1932398, "regularMarketVolume": 1932398, "averageVolume": 2102015, "averageVolume10days": 1465220, "averageDailyVolume10Day": 1465220, "bid": 31.26, "ask": 31.33, "bidSize": 3, "askSize": 3, "marketCap": 19410143232, "fiftyTwoWeekLow": 17.235, "fiftyTwoWeekHigh": 33.65, "allTimeHigh": 103.19, "allTimeLow": 0.654, "priceToSalesTrailing12Months": 5.047272, "fiftyDayAverage": 30.8918, "twoHundredDayAverage": 24.468426, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -1341329408, "profitMargins": 0.41169998, "floatShares": 60849374, "sharesOutstanding": 615993070, "sharesShort": 11896539, "sharesShortPriorMonth": 10539384, "sharesShortPreviousMonthDate": 1761868800, "dateShortInterest": 1764288000, "sharesPercentSharesOut": 0.019299999, "heldPercentInsiders": 0.0, "heldPercentInstitutions": 0.1029, "shortRatio": 6.53, "shortPercentOfFloat": 0.0195, "impliedSharesOutstanding": 619934330, "bookValue": 93.41, "priceToBook": 0.33518893, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "earningsQuarterlyGrowth": 1.016, "netIncomeToCommon": 1583268864, "trailingEps": 2.29, "forwardEps": 1.51496, "lastSplitFactor": "5:1", "lastSplitDate": 1525132800, "enterpriseToRevenue": -0.349, "enterpriseToEbitda": -0.911, "52WeekChange": 0.61338663, "SandP52WeekChange": 0.13613915, "quoteType": "EQUITY", "currentPrice": 31.31, "targetHighPrice": 48.0, "targetLowPrice": 26.0, "targetMeanPrice": 37.81429, "targetMedianPrice": 38.0, "recommendationMean": 1.5, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 7, "totalCash": 3411000064, "totalCashPerShare": 55.403, "ebitda": 1472946816, "totalDebt": 142000000, "quickRatio": 6.015, "currentRatio": 6.034, "totalRevenue": 3845670144, "debtToEquity": 2.469, "revenuePerShare": 6.1295, "returnOnAssets": 0.13377, "returnOnEquity": 0.29413, "grossProfits": 3628929536, "freeCashflow": 955981952, "operatingCashflow": 1368800768, "earningsGrowth": 1.076, "revenueGrowth": 0.174, "grossMargins": 0.94364, "ebitdaMargins": 0.38301, "operatingMargins": 0.44912, "financialCurrency": "USD", "symbol": "GMAB", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "postMarketPrice": 31.19, "postMarketChange": -0.11999893, "regularMarketChange": -0.9899998, "regularMarketDayRange": "31.24 - 31.9", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 2102015, "fiftyTwoWeekLowChange": 14.074999, "fiftyTwoWeekLowChangePercent": 0.81665206, "fiftyTwoWeekRange": "17.235 - 33.65", "fiftyTwoWeekHighChange": -2.340002, "fiftyTwoWeekHighChangePercent": -0.069539435, "fiftyTwoWeekChangePercent": 61.33866, "corporateActions": [], "postMarketTime": 1765586675, "regularMarketTime": 1765573202, "exchange": "NMS", "messageBoardId": "finmb_665704", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": -3.0650148, "regularMarketPrice": 31.31, "marketState": "CLOSED", "shortName": "Genmab A/S", "longName": "Genmab A/S", "earningsTimestamp": 1770325200, "earningsTimestampStart": 1770325200, "earningsTimestampEnd": 1770325200, "earningsCallTimestampStart": 1762448400, "earningsCallTimestampEnd": 1762448400, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": 2.29, "epsForward": 1.51496, "epsCurrentYear": 1.91539, "priceEpsCurrentYear": 16.34654, "fiftyDayAverageChange": 0.41819954, "fiftyDayAverageChangePercent": 0.013537558, "twoHundredDayAverageChange": 6.8415737, "twoHundredDayAverageChangePercent": 0.27960825, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.5 - Strong Buy", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1243863000000, "postMarketChangePercent": -0.38326073, "trailingPegRatio": 0.6047, "__fetch_time": "2025-12-14"}]